{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T10:55:02Z","timestamp":1781002502168,"version":"3.54.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,12,6]],"date-time":"2021-12-06T00:00:00Z","timestamp":1638748800000},"content-version":"vor","delay-in-days":5,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Musculoskelet Disord"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>There is no standard treatment for giant cell tumors of the sacrum. We compared the outcomes and complications in patients with sacral giant cell tumors who underwent intralesional nerve-sparing surgery with or without (neo-) adjuvant therapies versus those who underwent non-surgical treatment (denosumab therapy and\/or embolization).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We retrospectively investigated 15 cases of sacral giant cell tumors treated at two institutions between 2005 and 2020. Nine patients underwent intralesional nerve-sparing surgery with or without (neo-) adjuvant therapies, and six patients received non-surgical treatment. The mean follow-up period was 85\u2009months for the surgical group (range, 25\u2013154\u2009months) and 59\u2009months (range, 17\u201394\u2009months) for the non-surgical group.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The local recurrence rate was 44% in the surgical group, and the tumor progression rate was 0% in the non-surgical group. There were two surgery-related complications (infection and bladder laceration) and three denosumab-related complications (apical granuloma of the tooth, stress fracture of the sacroiliac joint, and osteonecrosis of the jaw). In the surgical group, the mean modified Biagini score (bowel, bladder, and motor function) was 0.9; in the non-surgical group, it was 0.5. None of the 11 female patients became pregnant or delivered a baby after developing a sacral giant cell tumor.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The cure rate of intralesional nerve-sparing surgery is over 50%. Non-surgical treatment has a similar risk of complications to intralesional nerve-sparing surgery and has better functional outcomes than intralesional nerve-sparing surgery, but patients must remain on therapy over time. Based on our results, the decision on the choice of treatment for sacral giant cell tumors could be discussed between the surgeon and the patient based on the tumor size and location.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12891-021-04907-0","type":"journal-article","created":{"date-parts":[[2021,12,6]],"date-time":"2021-12-06T16:02:38Z","timestamp":1638806558000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Intralesional nerve-sparing surgery versus non-surgical treatment for giant cell tumor of the sacrum"],"prefix":"10.1186","volume":"22","author":[{"given":"Shinji","family":"Tsukamoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolin","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas F.","family":"Mavrogenis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanya","family":"Honoki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhito","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Spinnato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide Maria","family":"Donati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Costantino","family":"Errani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,12,6]]},"reference":[{"key":"4907_CR1","unstructured":"Flanagan AM, Larousserie F, O\u2019Donnell PG, Yoshida A. Giant Cell Tumour of Bone. In: The WHO Classification of Tumours Editorial Board. WHO classification of tumours, 5th ed: Soft Tissue and Bone Tumours. Lyon: IARC; 2020. p. 440\u20136."},{"key":"4907_CR2","doi-asserted-by":"publisher","first-page":"106","DOI":"10.2106\/00004623-198769010-00018","volume":"69","author":"M Campanacci","year":"1987","unstructured":"Campanacci M, Baldini N, Boriani S, Sudanese A. Giant-cell tumor of bone. J Bone Joint Surg Am. 1987;69:106\u201314.","journal-title":"J Bone Joint Surg Am"},{"key":"4907_CR3","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000007799","volume":"96","author":"T Ji","year":"2017","unstructured":"Ji T, Yang Y, Wang Y, Sun K, Guo W. Combining of serial embolization and denosumab for large sacropelvic giant cell tumor: case report of 3 cases. Medicine (Baltimore). 2017;96:e7799.","journal-title":"Medicine (Baltimore)"},{"key":"4907_CR4","doi-asserted-by":"publisher","first-page":"417","DOI":"10.2214\/ajr.174.2.1740417","volume":"174","author":"J Llauger","year":"2000","unstructured":"Llauger J, Palmer J, Amores S, Bagu\u00e9 S, Camins A. Primary tumors of the sacrum: diagnostic imaging. AJR Am J Roentgenol. 2000;174:417\u201324.","journal-title":"AJR Am J Roentgenol"},{"key":"4907_CR5","doi-asserted-by":"publisher","first-page":"E2","DOI":"10.3171\/foc.2003.15.2.2","volume":"15","author":"BJ Manaster","year":"2003","unstructured":"Manaster BJ, Graham T. Imaging of sacral tumors. Neurosurg Focus. 2003;15:E2.","journal-title":"Neurosurg Focus"},{"key":"4907_CR6","doi-asserted-by":"publisher","first-page":"2954","DOI":"10.1007\/s11999-010-1448-8","volume":"468","author":"P Ruggieri","year":"2010","unstructured":"Ruggieri P, Mavrogenis AF, Ussia G, Angelini A, Papagelopoulos PJ, Mercuri M. Recurrence after and complications associated with adjuvant treatments for sacral giant cell tumor. Clin Orthop Relat Res. 2010;468:2954\u201361.","journal-title":"Clin Orthop Relat Res"},{"key":"4907_CR7","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1007\/s00586-009-1270-8","volume":"19","author":"R Thangaraj","year":"2010","unstructured":"Thangaraj R, Grimer RJ, Carter SR, Stirling AJ, Spilsbury J, Spooner D. Giant cell tumour of the sacrum: a suggested algorithm for treatment. Eur Spine J. 2010;19:1189\u201394.","journal-title":"Eur Spine J"},{"key":"4907_CR8","doi-asserted-by":"crossref","unstructured":"Guo W, Ji T, Tang X, Yang Y. Outcome of conservative surgery for giant cell tumor of the sacrum. Spine (Phila Pa 1976). 2009;34:1025\u201331.","DOI":"10.1097\/BRS.0b013e31819d4127"},{"key":"4907_CR9","doi-asserted-by":"crossref","unstructured":"Lim CY, Liu X, He F, Liang H, Yang Y, Ji T, et al. Retrospective cohort study of 68 sacral giant cell tumours treated with nerve-sparing surgery and evaluation on therapeutic benefits of denosumab therapy. Bone Joint J. 2020;102-B:177\u201385.","DOI":"10.1302\/0301-620X.102B2.BJJ-2019-0813.R1"},{"key":"4907_CR10","doi-asserted-by":"crossref","unstructured":"Zhao Y, Tang X, Yan T, Ji T, Yang R, Guo W. Risk factors for the local recurrence of giant cell tumours of the sacrum treated with nerve-sparing surgery. Bone Joint J 2020;102-B:1392\u20138.","DOI":"10.1302\/0301-620X.102B10.BJJ-2020-0276.R1"},{"key":"4907_CR11","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1016\/S1470-2045(13)70277-8","volume":"14","author":"S Chawla","year":"2013","unstructured":"Chawla S, Henshaw R, Seeger L, Choy E, Blay J-Y, Ferrari S, et al. Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study. Lancet Oncol. 2013;14:901\u20138.","journal-title":"Lancet Oncol."},{"key":"4907_CR12","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.ejca.2017.01.028","volume":"76","author":"E Palmerini","year":"2017","unstructured":"Palmerini E, Chawla NS, Ferrari S, Sudan M, Picci P, Marchesi E, et al. Denosumab in advanced\/unresectable giant-cell tumour of bone (GCTB): for how long? Eur J Cancer. 2017;76:118\u201324.","journal-title":"Eur J Cancer"},{"key":"4907_CR13","doi-asserted-by":"publisher","first-page":"3647","DOI":"10.3390\/cancers13153647","volume":"13","author":"S Tsukamoto","year":"2021","unstructured":"Tsukamoto S, Mavrogenis AF, Kido A, Errani C. Current concepts in the treatment of giant cell tumors of bone. Cancers (Basel). 2021;13:3647.","journal-title":"Cancers (Basel)"},{"key":"4907_CR14","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1111\/os.12336","volume":"9","author":"S-H He","year":"2017","unstructured":"He S-H, Xu W, Sun Z-W, Liu W-B, Liu Y-J, Wei H-F, et al. Selective arterial embolization for the treatment of sacral and pelvic giant cell tumor: a systematic review. Orthop Surg. 2017;9:139\u201344.","journal-title":"Orthop Surg"},{"key":"4907_CR15","doi-asserted-by":"crossref","unstructured":"Puri A, Gupta SM, Gulia A, Shetty N, Laskar S. Giant cell tumors of the sacrum: is non-operative treatment effective? Eur Spine J 2020.","DOI":"10.1007\/s00586-020-06650-x"},{"key":"4907_CR16","doi-asserted-by":"publisher","first-page":"228","DOI":"10.3171\/2015.4.SPINE13215","volume":"24","author":"SV Domovitov","year":"2016","unstructured":"Domovitov SV, Chandhanayingyong C, Boland PJ, McKeown DG, Healey JH. Conservative surgery in the treatment of giant cell tumor of the sacrum: 35 years\u2019 experience. J Neurosurg Spine. 2016;24:228\u201340.","journal-title":"J Neurosurg Spine"},{"key":"4907_CR17","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.spinee.2014.08.445","volume":"15","author":"D Moran","year":"2015","unstructured":"Moran D, Zadnik PL, Taylor T, Groves ML, Yurter A, Wolinsky J-P, et al. Maintenance of bowel, bladder, and motor functions after sacrectomy. Spine J. 2015;15:222\u20139.","journal-title":"Spine J"},{"key":"4907_CR18","doi-asserted-by":"crossref","unstructured":"Langevelde KV, Vucht NV, Tsukamoto S, Mavrogenis AF, Errani C. Radiological assessment of Giant cell tumour of bone in the sacrum: from diagnosis to treatment response evaluation. Curr med Imaging. 2021.","DOI":"10.2174\/1573405617666210406121006"},{"key":"4907_CR19","doi-asserted-by":"crossref","unstructured":"Turcotte RE, Sim FH, Unni KK. Giant cell tumor of the sacrum. Clin Orthop Relat Res 1993;:215-21.","DOI":"10.1097\/00003086-199306000-00025"},{"key":"4907_CR20","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/410973","volume":"2012","author":"M Balke","year":"2012","unstructured":"Balke M, Henrichs MP, Gosheger G, Ahrens H, Streitbuerger A, Koehler M, et al. Giant cell tumors of the axial skeleton. Sarcoma. 2012;2012:410973.","journal-title":"Sarcoma."},{"key":"4907_CR21","doi-asserted-by":"publisher","first-page":"2182","DOI":"10.1007\/s00586-015-3978-y","volume":"24","author":"K-H Chen","year":"2015","unstructured":"Chen K-H, Wu P-K, Chen C-F, Chen W-M. Zoledronic acid-loaded bone cement as a local adjuvant therapy for giant cell tumor of the sacrum after intralesional curettage. Eur Spine J. 2015;24:2182\u20138.","journal-title":"Eur Spine J"},{"key":"4907_CR22","first-page":"453","volume":"23","author":"Z Chen","year":"2018","unstructured":"Chen Z, Yang Y, Guo W, Yang R, Tang X, Yan T, et al. Therapeutic benefits of neoadjuvant and post-operative denosumab on sacral giant cell tumor: a retrospective cohort study of 30 cases. J BUON. 2018;23:453\u20139.","journal-title":"J BUON"},{"key":"4907_CR23","doi-asserted-by":"publisher","first-page":"2830","DOI":"10.1002\/cncr.11383","volume":"97","author":"Y Kollender","year":"2003","unstructured":"Kollender Y, Meller I, Bickels J, Flusser G, Issakov J, Merimsky O, et al. Role of adjuvant cryosurgery in intralesional treatment of sacral tumors. Cancer. 2003;97:2830\u20138.","journal-title":"Cancer."},{"key":"4907_CR24","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1016\/j.spinee.2012.06.014","volume":"12","author":"G Li","year":"2012","unstructured":"Li G, Fu D, Chen K, Ma X, Sun M, Sun W, et al. Surgical strategy for the management of sacral giant cell tumors: a 32-case series. Spine J. 2012;12:484\u201391.","journal-title":"Spine J"},{"key":"4907_CR25","first-page":"69","volume":"30","author":"C Martin","year":"2010","unstructured":"Martin C, McCarthy EF. Giant cell tumor of the sacrum and spine: series of 23 cases and a review of the literature. Iowa Orthop J. 2010;30:69\u201375.","journal-title":"Iowa Orthop J"},{"key":"4907_CR26","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1007\/s00586-014-3263-5","volume":"23","author":"L van der Heijden","year":"2014","unstructured":"van der Heijden L, van de Sande MAJ, van der Geest ICM, Schreuder HWB, van Royen BJ, Jutte PC, et al. Giant cell tumors of the sacrum--a nationwide study on midterm results in 26 patients after intralesional excision. Eur Spine J. 2014;23:1949\u201362.","journal-title":"Eur Spine J"},{"key":"4907_CR27","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.jocn.2020.07.057","volume":"80","author":"J Wang","year":"2020","unstructured":"Wang J, Du Z, Yang R, Tang X, Yan T, Guo W. Analysis of clinical outcome for adolescent patients undergoing conservative nerve-sparing surgery based on the proposed resection classification for sacral giant cell tumor. J Clin Neurosci. 2020;80:23\u20139.","journal-title":"J Clin Neurosci"},{"key":"4907_CR28","doi-asserted-by":"publisher","first-page":"716","DOI":"10.3171\/2016.10.SPINE151197","volume":"26","author":"W Xu","year":"2017","unstructured":"Xu W, Wang Y, Wang J, Yang X, Liu W, Zhou W, et al. Long-term administration of bisphosphonate to reduce local recurrence of sacral giant cell tumor after nerve-sparing surgery. J Neurosurg Spine. 2017;26:716\u201321.","journal-title":"J Neurosurg Spine."},{"key":"4907_CR29","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000013139","volume":"97","author":"Y Yang","year":"2018","unstructured":"Yang Y, Li Y, Liu W, Xu H, Niu X. A nonrandomized controlled study of sacral giant cell tumors with preoperative treatment of denosumab. Medicine (Baltimore). 2018;97:e13139.","journal-title":"Medicine (Baltimore)"},{"key":"4907_CR30","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1111\/os.12561","volume":"11","author":"R-Z Zhang","year":"2019","unstructured":"Zhang R-Z, Ma T-X, Qi D-W, Zhao M, Hu T, Zhang G-C. Short-term preoperative denosumab with surgery in unresectable or recurrent giant cell tumor of bone. Orthop Surg. 2019;11:1101\u20138.","journal-title":"Orthop Surg"},{"key":"4907_CR31","doi-asserted-by":"publisher","first-page":"755","DOI":"10.2106\/00004623-198264050-00015","volume":"64","author":"HW Sung","year":"1982","unstructured":"Sung HW, Kuo DP, Shu WP, Chai YB, Liu CC, Li SM. Giant-cell tumor of bone: analysis of two hundred and eight cases in Chinese patients. J Bone Joint Surg Am. 1982;64:755\u201361.","journal-title":"J Bone Joint Surg Am"},{"key":"4907_CR32","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.jot.2018.10.003","volume":"18","author":"X Niu","year":"2019","unstructured":"Niu X, Yang Y, Wong KC, Huang Z, Ding Y, Zhang W. Giant cell tumour of the bone treated with denosumab: how has the blood supply and oncological prognosis of the tumour changed? J Orthop Translat. 2019;18:100\u20138.","journal-title":"J Orthop Translat"},{"key":"4907_CR33","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.2214\/ajr.136.6.1127","volume":"136","author":"VP Chuang","year":"1981","unstructured":"Chuang VP, Soo CS, Wallace S, Benjamin RS. Arterial occlusion: management of giant cell tumor and aneurysmal bone cyst. AJR Am J Roentgenol. 1981;136:1127\u201330.","journal-title":"AJR Am J Roentgenol"},{"key":"4907_CR34","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1097\/01.brs.0000261558.94247.8d","volume":"32","author":"HS Hosalkar","year":"2007","unstructured":"Hosalkar HS, Jones KJ, King JJ, Lackman RD. Serial arterial embolization for large sacral giant-cell tumors: mid- to long-term results. Spine. 2007;32:1107\u201315.","journal-title":"Spine."},{"key":"4907_CR35","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1302\/0301-620X.84B6.0840873","volume":"84","author":"RD Lackman","year":"2002","unstructured":"Lackman RD, Khoury LD, Esmail A, Donthineni-Rao R. The treatment of sacral giant-cell tumours by serial arterial embolisation. J Bone Joint Surg Br. 2002;84:873\u20137.","journal-title":"J Bone Joint Surg Br"},{"key":"4907_CR36","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1002\/cncr.10803","volume":"95","author":"PP Lin","year":"2002","unstructured":"Lin PP, Guzel VB, Moura MF, Wallace S, Benjamin RS, Weber KL, et al. Long-term follow-up of patients with giant cell tumor of the sacrum treated with selective arterial embolization. Cancer. 2002;95:1317\u201325.","journal-title":"Cancer."},{"key":"4907_CR37","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1186\/2193-1801-2-666","volume":"2","author":"K Nakanishi","year":"2013","unstructured":"Nakanishi K, Osuga K, Hori S, Hamada K, Hashimoto N, Araki N, et al. Transarterial embolization (TAE) of sacral giant cell tumor (GCT) using spherical parmanent embolic material superabsorbant polymer microsphere (SAP-MS). Springerplus. 2013;2:666.","journal-title":"Springerplus."},{"key":"4907_CR38","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1186\/1471-2407-10-462","volume":"10","author":"M Balke","year":"2010","unstructured":"Balke M, Campanacci L, Gebert C, Picci P, Gibbons M, Taylor R, et al. Bisphosphonate treatment of aggressive primary, recurrent and metastatic Giant cell tumour of bone. BMC Cancer. 2010;10:462.","journal-title":"BMC Cancer"},{"key":"4907_CR39","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1007\/s10147-010-0048-7","volume":"15","author":"H Onishi","year":"2010","unstructured":"Onishi H, Kaya M, Wada T, Nagoya S, Sasaki M, Yamashita T. Giant cell tumor of the sacrum treated with selective arterial embolization. Int J Clin Oncol. 2010;15:416\u20139.","journal-title":"Int J Clin Oncol"},{"key":"4907_CR40","doi-asserted-by":"publisher","first-page":"E4","DOI":"10.3171\/foc.2003.15.2.4","volume":"15","author":"ON Gottfried","year":"2003","unstructured":"Gottfried ON, Schmidt MH, Stevens EA. Embolization of sacral tumors. Neurosurg Focus. 2003;15:E4.","journal-title":"Neurosurg Focus"},{"key":"4907_CR41","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1007\/s11999-008-0483-1","volume":"467","author":"X Tang","year":"2009","unstructured":"Tang X, Guo W, Yang R, Tang S, Ji T. Risk factors for blood loss during sacral tumor resection. Clin Orthop Relat Res. 2009;467:1599\u2013604.","journal-title":"Clin Orthop Relat Res"},{"key":"4907_CR42","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1016\/S1470-2045(19)30663-1","volume":"20","author":"S Chawla","year":"2019","unstructured":"Chawla S, Blay J-Y, Rutkowski P, Le Cesne A, Reichardt P, Gelderblom H, et al. Denosumab in patients with giant-cell tumour of bone: a multicentre, open-label, phase 2 study. Lancet Oncol. 2019;20:1719\u201329.","journal-title":"Lancet Oncol"},{"key":"4907_CR43","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.reprotox.2013.07.018","volume":"42","author":"JL Bussiere","year":"2013","unstructured":"Bussiere JL, Pyrah I, Boyce R, Branstetter D, Loomis M, Andrews-Cleavenger D, et al. Reproductive toxicity of denosumab in cynomolgus monkeys. Reprod Toxicol. 2013;42:27\u201340.","journal-title":"Reprod Toxicol"},{"key":"4907_CR44","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/j.bbrc.2017.07.154","volume":"491","author":"N Okamatsu","year":"2017","unstructured":"Okamatsu N, Sakai N, Karakawa A, Kouyama N, Sato Y, Inagaki K, et al. Biological effects of anti-RANKL antibody administration in pregnant mice and their newborns. Biochem Biophys Res Commun. 2017;491:614\u201321.","journal-title":"Biochem Biophys Res Commun"}],"container-title":["BMC Musculoskeletal Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12891-021-04907-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12891-021-04907-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12891-021-04907-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,6]],"date-time":"2021-12-06T16:02:45Z","timestamp":1638806565000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmusculoskeletdisord.biomedcentral.com\/articles\/10.1186\/s12891-021-04907-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["4907"],"URL":"https:\/\/doi.org\/10.1186\/s12891-021-04907-0","relation":{},"ISSN":["1471-2474"],"issn-type":[{"value":"1471-2474","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"3 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted according to the guidelines of the Declaration of Helsinki and was approved by the institutional review board of each institution.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Informed consent was obtained from all individual participants in IRCCS Istituto Ortopedico Rizzoli, and the requirement for written consent from participants in Nara Medical University was waived, because an \u201copt-out\u201d process was used and the study has the retrospective nature.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1023"}}